Kathleen Uhl, MD currently serves as the Director for the Office of Generic Drugs in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). This office is responsible for the review and approval of Abbreviated New Drug Applications (ANDAs) and is largely tasked with implementing the Generic Drug User Fee Amendments (GDUFA). She received her undergraduate degree from Temple University and her medical degree from the Medical College of Pennsylvania.